Smartleaf Asset Management LLC Sells 2,155 Shares of Genmab A/S (NASDAQ:GMAB)

Smartleaf Asset Management LLC cut its stake in shares of Genmab A/S (NASDAQ:GMAB) by 32.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,536 shares of the company’s stock after selling 2,155 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Genmab A/S were worth $94,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares during the period. Cromwell Holdings LLC grew its stake in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after acquiring an additional 2,496 shares during the period. R Squared Ltd bought a new position in shares of Genmab A/S during the 4th quarter valued at approximately $93,000. Blue Trust Inc. grew its stake in shares of Genmab A/S by 33.4% during the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after acquiring an additional 1,442 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after purchasing an additional 827 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on GMAB shares. Leerink Partnrs upgraded Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research note on Thursday, February 13th. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Price Performance

Shares of GMAB opened at $24.14 on Friday. The stock has a market capitalization of $15.98 billion, a price-to-earnings ratio of 13.87, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. Genmab A/S has a 1 year low of $18.64 and a 1 year high of $31.88. The business’s 50 day simple moving average is $21.28 and its 200-day simple moving average is $22.66.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.